Immutep Ltd
NASDAQ:IMMP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Aarti Drugs Ltd
NSE:AARTIDRUGS
|
IN |
|
Digital Realty Trust Inc
NYSE:DLR
|
US |
|
Xiamen Comfort Science & Technology Group Co Ltd
SZSE:002614
|
CN |
|
Kirloskar Brothers Ltd
NSE:KIRLOSBROS
|
IN |
|
Ginlong Technologies Co Ltd
SZSE:300763
|
CN |
|
G
|
Gujarat Cotex Ltd
BSE:514386
|
IN |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (10.6), the stock would be worth $13.02 (2 107% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.5 | $0.59 |
0%
|
| Industry Average | 10.6 | $13.02 |
+2 107%
|
| Country Average | 16.8 | $20.55 |
+3 382%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$-33.3m
|
/ |
Jan 2026
AU$-89m
|
= |
|
|
$-33.3m
|
/ |
Jun 2026
AU$-61m
|
= |
|
|
$-33.3m
|
/ |
Jun 2027
AU$-64.5m
|
= |
|
|
$-33.3m
|
/ |
Jun 2028
AU$-72.3m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Immutep Ltd
NASDAQ:IMMP
|
54.5m USD | 0.5 | -1.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.6B USD | 20 | 86.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.9B USD | 14 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.4B USD | 15 | 19.5 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.9B USD | 22 | 28.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79B USD | 14.8 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.5B EUR | 42.3 | 38.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 13.1 | 30.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10.7 |
| Median | 16.8 |
| 70th Percentile | 24.5 |
| Max | 6 797.5 |
Other Multiples
Immutep Ltd
Glance View
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The firm has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.
